| Biochemistry
| [0003]
|
| Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil 2-14C by preneoplastic rat liver and rat hepatoma
| [0003]
|
| Fluorinated pyrimidines, a new class of tumor-inhibitory compounds
| [0003]
|
| a novel agent for the treatment of solid tumors
| [0004]
|
| 5-Fluorouracil. Mechanisms of action and clinical strategies
| [0004]
|
| Lancet
| [0005]
|
| The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
| [0005]
|
| Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies
| [0005]
|
| Fifteen-year trends in metastatic breast cancer survival in Greece
| [0005]
|
| Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer
| [0006]
|
| Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer
| [0006]
|
| Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group
| [0007]
|
| Randomized comparison of cisplatin plus fluorouracil and carboplatin plus 5-fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study
| [0007]
|
| GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11
| [0008]
[0009]
|
| Global cancer statistics
| [0009]
|
| Guidelines 2000 for colon and rectal cancer surgery
| [0010]
|
| Colorectal cancer
| [0011]
|
| The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group
| [0011]
|
| Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis
| [0012]
|
| 5,10-Methylene-5,6,7,8-tetrahydrofolate conformational transitions upon binding to thymidylate synthase: molecular mechanics and continuum solvent studies
| [0012]
|
| Metabolism and mechanism of action of 5-fluorouracil
| [0012]
|
| The impact of folate status on the efficacy of colorectal cancer treatment
| [0012]
|
| Chemical stability and human plasma pharmacokinetics of reduced folates
| [0014]
|
| Phase III Multicenter Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor®/5-Fluorouracil/Bevacizumab Versus Leucovorin/5-Fluorouracil/ Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma Clinical Colorectal
| [0015]
|
| CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy
| [0015]
|
| Effects of the diastereoisomers of methylenetetrahydrofolate on the reaction catalyzed by thymidylate synthetase
| [0015]
[0064]
|
| Clin Colorectal Cancer
| [0017]
|
| New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)
| [0024]
|
| Clinical Cancer Research
| [0030]
[0064]
|
| Cancer Chemother Pharmacol
| [0034]
|
| Cancer Res.
| [0035]
|
| Pooled analysis of safety and efficacy of oxaliplatin plus 5-fluorouracil/leucovorin administrated bimonthly in elderly patients with colorectal cancer
| [0037]
|
| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
| [0038]
|
| Oral uracil and tegafur plus leucovorin compared with iv 5-FU and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06
| [0039]
|
| Clinical Colorectal Cancer
| [0070]
|